---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004780"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:44:08.976962+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics Q2 net sales up 54% to $23.2M; raises full-year guidance

## Summary
- Net sales $23.2M (+54% YoY); DME channel $18.6M (+31%), PBP channel $4.6M (+498%).
- Installed base 24,085 users (+200%); new patient starts 4,934 (+57%), 71% from MDI.
- Net loss $16.9M (negative 73% of sales) vs $14.5M (negative 96%) in Q2 2024.
- Adjusted EBITDA -$14.5M (negative 63% of sales) vs -$10.0M (negative 66%).
- Cash and investments $280.9M as of June 30; raised full-year 2025 revenue and adjusted EBITDA guidance.

## SEC filing metadata
- accession: 0001171843-25-004780
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184325004780/0001171843-25-004780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184325004780/f8k_072925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004780
- JSON: https://secwatch.observer/filing/0001171843-25-004780.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.